Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab
Author:
Affiliation:
1. Oregon Medical Research Center, Portland, OR, USA;
2. Eli Lilly and Company, Indianapolis, IN, USA;
3. Bakersfield Dermatology, Bakersfield, CA, USA;
4. Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Funder
Eli Lilly and Company
Publisher
Informa UK Limited
Subject
Dermatology
Link
https://www.tandfonline.com/doi/pdf/10.1080/09546634.2017.1365114
Reference22 articles.
1. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
2. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
3. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
4. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
5. Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study;Journal of Clinical Medicine;2024-07-09
2. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor);Dermatology and Therapy;2024-02
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12
4. Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry;Dermatology and Therapy;2022-12-23
5. Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real‐world retrospective study and literature review;Dermatologic Therapy;2022-11-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3